STOCK TITAN

Ibio Stock Price, News & Analysis

IBIO NYSE

Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.

iBio, Inc. (IBIO) is a biotechnology innovator providing end-to-end CDMO services and AI-driven solutions for biotherapeutics development. This page serves as the definitive source for all official company announcements, regulatory filings, and operational updates.

Investors and industry observers will find timely access to earnings reports, strategic partnerships, regulatory milestones, and technology advancements related to iBio's vaccine development and precision antibody platforms. Our curated feed ensures transparent tracking of the company's progress in accelerating biopharmaceutical production from discovery to commercialization.

All content is sourced directly from iBio's corporate communications, maintaining factual accuracy and compliance with financial disclosure standards. Bookmark this page for efficient monitoring of IBIO's developments in artificial intelligence applications for drug discovery, manufacturing expansions, and clinical trial updates.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
conferences
Rhea-AI Summary

iBio announced a breakthrough in bispecific immuno-oncology therapies during a presentation at Carterra's symposium. The Company unveiled a panel of CD3 T-cell binding antibodies, poised to advance T-cell-redirecting bispecific antibodies. These antibodies aim to enhance the immune response against tumors by binding to both T cells and tumor-specific antigens. iBio utilized its patented epitope steering technology and AI-based antibody optimizer to overcome challenges like severe toxicities and lack of cross-reactivity with non-human primates. CEO Martin Brenner highlighted the addition of these antibodies as a valuable asset for enhancing treatment efficacy and safety in future pipeline programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.12%
Tags
none
-
Rhea-AI Summary

iBio, a company specializing in precision antibody immunotherapies, has advanced its anti-CCR8 antibody program into preclinical in vivo testing. This program targets T-regulatory cells, which are pivotal in cancer immunosuppression. The anti-CCR8 antibody aims to selectively deplete Tregs, enhancing the immune system's ability to combat tumors while minimizing potential adverse effects. The development follows the success of iBio’s existing program, IBIO-101, an anti-CD25 antibody. iBio highlights its patented AI epitope steering platform as key to discovering high-value GPCR targets, indicating a promising future for antibody-based therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
-
Rhea-AI Summary

iBio has announced its latest immune-oncology program targeting MUC16, a protein overexpressed in various solid tumors, including ovarian and pancreatic cancers. Utilizing its patented epitope steering AI platform, iBio's new monoclonal antibodies aim to bind to an unmodifiable region of MUC16, enhancing the effectiveness of cancer treatment by circumventing tumor evasion mechanisms. This addition expands iBio's immuno-oncology portfolio, which already includes programs targeting other cancer-specific proteins. The company emphasizes its commitment to advancing innovative treatments in the biopharmaceutical space.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
97.33%
Tags
none
Rhea-AI Summary

iBio Inc. (NYSEA:IBIO) announced the issuance of U.S. Patent No. 11,545,238, which covers a machine learning model for designing engineered peptides aimed at improving therapeutic antibody precision. This patent reinforces iBio's leadership in AI-driven drug discovery and strengthens its competitive position in the biotech sector. The RubrYc Discovery Engine is highlighted as a key innovation, facilitating faster identification of effective molecules for challenging drug targets, particularly in hard-to-treat cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none

FAQ

What is the current stock price of Ibio (IBIO)?

The current stock price of Ibio (IBIO) is $0.9281 as of June 13, 2025.

What is the market cap of Ibio (IBIO)?

The market cap of Ibio (IBIO) is approximately 15.3M.
Ibio

NYSE:IBIO

IBIO Rankings

IBIO Stock Data

15.31M
15.75M
7.21%
26.65%
4.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK